Tumor bank Ovarian Cancer Network

Ovarian cancer has one of the highest mortality rates of the common epithelial tumours, despite sensitivity to many cytotoxic agents. Late diagnosis, the lack of an effective diagnostic marker, and poor capacity to monitor small volume disease are contributory factors. There has been significant progress in the biology of the disease. The European activities in translational research in ovarian cancer fragmented. Therefore a multidisciplinary cooperation between researchers as also a high qualitive biobank focusing on ovarian cancer is needed: EUTROC and TOC intend to facilitate the rapid introduction of cutting edge therapy.

Anticancer Agents/Chemoresistance; Metastasis/Invasion/Tumor Environment; Tumor Immunology; Signaling/Genetics/Epigenetics/Molecular Profiling; Oncogenes/Tumor Suppressors
Head of Project:

Univ. Prof. Dr. Jalid Sehouli
Charité - Universitätsmedizin Berlin
Department of Gynecology CVK
Tel. 450-564052
Fax 450-564952
Additional Head of Project:

Prof. Dr. Jalid Sehouli, Dr. med. Ioana Braicu
Additional Member of Project:

PD. Christina Fotopoulou, Dr. med. Radoslav Chekerov
Begin/End of Project:

01/2011 - 12/2011
Funded by:

Universitäre Forschungsförderung Charité


Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, Sehouli J, Darb-Esfahani S, Denkert C, Thomssen C, Hauptmann S, Lund A, Marine JC, Bartel F. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Braicu I, Fotopoulou C, Sehouli J. Prognosefaktoren und translationale Forschung. Onkologie heute 2010;1: 40-43. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
Proposal of Project:

TOCEUTROC Network engl.pdf